(4S,4'S,5S,5'S)-2,2'-(1-Methylethylidene)bis(4,5-dihydro-4,5-diphenyloxazole)

Catalog No. :
ACTURS348
CAS No. :
529489-04-1
Molecular Formula :
C33H30N2O2
Molecular Weight :
486.61

IUPAC Name:(4S,4'S,5S,5'S)-2,2'-(propane-2,2-diyl)bis(4,5-diphenyl-4,5-dihydrooxazole)

(4S,4'S,5S,5'S)-2,2'-(1-Methylethylidene)bis(4,5-dihydro-4,5-diphenyloxazole) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$62.00Login to see priceIn stockInquiry
1g97%$208.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(4S,4'S,5S,5'S)-2,2'-(1-Methylethylidene)bis(4,5-dihydro-4,5-diphenyloxazole)
IUPAC Name(4S,4'S,5S,5'S)-2,2'-(propane-2,2-diyl)bis(4,5-diphenyl-4,5-dihydrooxazole)
MDL No.-
Molecular FormulaC33H30N2O2
Molecular Weight486.61
SMILESCC(C)(C1=N[C@@H](C2=CC=CC=C2)[C@H](C2=CC=CC=C2)O1)C1=N[C@@H](C2=CC=CC=C2)[C@H](C2=CC=CC=C2)O1
InChI KeyZWWGNCSTEMMQOQ-KRCBVYEFSA-N
SynonymOxazole, 2,2'-(1-methylethylidene)bis[4,5-dihydro-4,5-diphenyl-, (4S,4'S,5S,5'S)-;(4S,4'S,5S,5'S)-2,2'-(1-Methylethylidene)bis(4,5-dihydro-4,5-diphenyloxazole);(S,S)-BisPh-propabBox
CAS No.529489-04-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACTURS348 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTURS348 route product structure diagram
    ACTURS348529489-04-1 In Stock
Inquiry

2. ACTURS348 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTURS348 route compound structure diagram
    ACTURS348529489-04-1 In Stock
  2. Plus
  3. ACNXUH296 route compound structure diagram
    ACNXUH2961774-47-6 In Stock
  4. Then
  5. ACTURS348 route product structure diagram
    ACTURS348529489-04-1 In Stock
Inquiry

Comments (0)